What Eskayef Pharmaceuticals does

Eskayef Pharmaceuticals Limited is a Bangladesh-based pharmaceutical manufacturer founded in 1990 when Transcom Group acquired the Bangladesh operations of SK&F, USA. Operating as a core subsidiary of the diversified Transcom Group, the company manufactures and sells branded generic formulations, oncology medicines, hormone products, and animal health solutions through its dedicated AHD (Animal Health Division). Production is anchored by GMP-accredited facilities developed with technical support from European consulting firms, and the company holds regulatory clearances from the US FDA, UK MHRA, EU GMP, TGA Australia, VMD UK, and ANVISA Brazil — including the first US FDA approval for an injectable manufacturing facility in Bangladesh.

The company's portfolio spans gastrointestinal products (e.g., Esoral MUPS), antidiabetics (Zepter, a tirzepatide-based GLP-1/GIP dual agonist), nephrologicals (Fericit), neurologicals (Tufnil), vitamins and minerals (Xinc, Ostocal), and a dedicated Eskayef Oncology line for cancer treatments. Eskayef distributes these products domestically through a Bangladesh distribution network and internationally by exporting to over 70 countries, generating revenue primarily through prescription and over-the-counter pharmaceutical sales rather than via software or platform-based monetization.

Eskayef is led by Simeen Rahman as Managing Director & CEO, with Latifur Rahman as Founder Chairman of parent Transcom Group. The company operates a corporate marketing approach through its website (skfbd.com), social media channels, and CSR healthcare outreach partnerships (e.g., with the Faraaz Hossain Foundation), and remains a privately held subsidiary with no public listing or external institutional investment disclosed.

Name

Eskayef Pharmaceuticals

Legal name

Eskayef Pharmaceuticals Limited

Website

https://skfbd.com

Company type

Private

Founded year

1990

Operating status

Operating

Headcount range

1,001–5,000 employees

Ownership category

akta.pro rank

Product category

Branded Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Specialty Pharmaceutical Distributors (HLAIAJAB)

akta.pro secondary industries

Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH), Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ), Endocrinology & Metabolic Specialty Pharmaceuticals (HLAIACAD)

Keywords

• Pharmaceutical manufacturing
• Branded generics
• Oncology medicines
• Animal health products
• Hormone formulations

Headquarters

HQ city

Dhaka

HQ country

Bangladesh

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales

Revenue model

1. Pharmaceutical Sales: Eskayef generates revenue through manufacturing and selling pharmaceutical products including formulations, oncology medicines, hormones, and animal health products across domestic and international markets.
2. International Export: Revenue from exporting pharmaceutical products to over 70 countries worldwide, with GMP-accredited manufacturing facilities meeting international regulatory standards.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Core offering

Eskayef Pharmaceuticals manufactures and markets finished pharmaceutical formulations across multiple therapeutic categories, including oncology medicines, hormone products for women's health, and animal health products. The company operates GMP-accredited production facilities that meet US FDA, UK MHRA, EU GMP, TGA Australia, VMD UK, and ANVISA Brazil standards, distributing products domestically in Bangladesh and exporting to more than 70 countries worldwide.

Product overview

Eskayef Pharmaceuticals Limited is a leading pharmaceutical company in Bangladesh offering a diverse portfolio of branded medicines across multiple therapeutic categories. The product portfolio includes formulations across therapeutic areas such as gastrointestinal products (Esoral MUPS), antidiabetics (Zepter), nephrologicals (Fericit), neurologicals (Tufnil), vitamins and minerals (Xinc, Ostocal), as well as specialized oncology products. The company also offers animal health solutions through its AHD (Animal Health Division) portfolio. Eskayef serves both domestic and international markets, exporting to over 70 countries.

Differentiator

Problem solved

Functional benefit

Brands

• Eskayef Oncology: Dedicated oncology division providing world-class cancer medicines.

Products and services

• Fericit Ferric Iron supplement used for the treatment of iron deficiency and related nephrological conditions. Marketed for healthcare providers and patients requiring iron repletion therapy.
• Zepter Tirzepatide-based antidiabetic medication positioned within the anti-diabetic therapeutic category, intended for adult patients with type 2 diabetes management.
• Eskayef Oncology Dedicated oncology division offering a portfolio of anti-cancer pharmaceutical formulations to oncologists, hospitals, and cancer care institutions in Bangladesh and international markets.
• Eskayef Hormone (Women's Health) Next-generation hormone portfolio focused on women's health, including hormone replacement and gynecological formulations for healthcare providers and patients.
• Animal Health Division (AHD) Veterinary pharmaceuticals product line offering animal health formulations such as Remivir, Paxovir, and Monuvir to veterinary professionals, farms, and livestock operators.
• Ostocal Calcium Carbonate preparation used for calcium supplementation and bone health, marketed to healthcare providers and patients in need of calcium repletion.
• Esoral Esomeprazole-based gastrointestinal product for the treatment of acid-related disorders including GERD and peptic ulcer disease.
• Etorix Etoricoxib-based NSAID formulation used for the management of pain and inflammation in musculoskeletal and arthritic conditions.
• Losectil Proton pump inhibitor (omeprazole) formulation used for gastric acid-related disorders, serving primary care physicians and gastroenterologists.
• Esoral MUPS Multiple Unit Pellet System formulation of esomeprazole offering modified-release delivery for gastrointestinal indications.
• Tufnil Tolfenamic acid formulation used for the treatment of neurological conditions including migraine and related pain disorders.
• Xinc Zinc Sulfate supplement used for zinc deficiency management and supporting nutritional therapy in clinical practice.

Named customers1 record

Segments4 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Four partnerships are on record, tiered minor.

• Faraaz Hossain FoundationminorStrategic or Co-development Partner · 1 July 2026Eskayef Pharmaceuticals coordinated and supplied medicines free of charge at free medical camps organized by the Faraaz Hossain Foundation across Brahmanbaria, Tangail, and Barishal districts in Bangladesh, serving approximately 1,300 people in memory of Faraaz Ayaaz Hossain.
• Transcom Distribution Company LtdminorOthers · 1 July 2026Transcom Distribution Company Ltd's Patuakhali branch held a milad mahfil in memory of Faraaz and the company's late chairman Latifur Rahman. Both Transcom Distribution and Eskayef are part of Transcom Group.
• Distressed Children & Infants InternationalminorStrategic or Co-development Partner · 3 December 2017Partner in healthcare outreach programs providing specialized medical services to patients in underserved districts including Cox's Bazar, Narsingdi, Bhola, Brahmanbaria and Rangpur.
• Centre for the Rehabilitation of the Paralysed (CRP)minorStrategic or Co-development Partner · 3 December 2017Partner in healthcare outreach; Eskayef donated 10 specialized standing wheelchairs to CRP and identified 50 cataract patients for fully funded surgeries as part of community support programs.

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Square Pharmaceuticals: Bangladesh's largest pharmaceutical company by domestic market share; manufactures and markets a broad portfolio of formulations across therapeutic categories with strong export presence. Closest direct domestic peer to Eskayef in scale, portfolio breadth, and Bangladesh-centric distribution model.
• Beximco Pharmaceuticals: Major Bangladeshi pharmaceutical manufacturer exporting to 50+ countries with US FDA-approved facilities and a diversified branded-generic portfolio. Directly comparable in geography, scale, regulatory ambitions, and therapeutic coverage to Eskayef.
• Renata Limited (Renata Pharma): One of the top Bangladeshi pharmaceutical manufacturers with animal health and consumer health adjacencies. Overlaps directly with Eskayef's human + animal health dual focus and Bangladesh-led commercial model.
• Incepta Pharmaceuticals: Bangladesh-based generic and specialty pharmaceutical manufacturer with growing export footprint and oncology capabilities. Comparable in therapeutic breadth, export orientation, and emerging international expansion profile.
• ACI Limited (pharma division): Bangladeshi conglomerate with a pharmaceuticals arm producing formulations, oncology, and animal health products. Operates in the same domestic market with overlapping therapeutic categories and similar export ambitions.

Broad incumbents

• Dr. Reddy's Laboratories: Large Indian global generics manufacturer with strong US FDA-approved injectables franchise and broad export footprint. Comparable in export-driven generics model and oncology/specialty adjacencies, though materially larger in scale and capital access.
• Cipla Limited: Indian global pharmaceutical major with broad generics, API, and specialty portfolio across emerging and regulated markets. Overlaps with Eskayef on respiratory, oncology, and chronic-disease therapeutic areas as well as emerging-market export strategy.
• Sun Pharmaceutical Industries: World's largest generic pharmaceutical company by revenue, with extensive US FDA footprint and broad branded-generic portfolio. Represents the scaled incumbent template for the regulated-market generics business model Eskayef is targeting.
• Lupin Limited: Indian global generics and specialty manufacturer with diversified therapeutic portfolio and US FDA-accredited facilities. Comparable in API-to-formulation integration, therapeutic breadth, and emerging-market presence.

Emerging players

• Zydus Lifesciences (Cadila): Indian pharmaceutical company with strong biosimilars, injectables, and emerging-market generics franchise. Comparable in injectable/oncology focus and pursuit of regulated-market approvals, though with broader biologics capability.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/channel/UCnWf60J3B2gyyHuhFnmZOSw
• Facebookweb.facebook.com/ESKAYEF
• LinkedInlinkedin.com/company/eskayef-pharmaceuticals-limited
• Instagraminstagram.com/eskayef.pharmaceuticals.ltd

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries2 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Eskayef Pharmaceuticals